Compare Stocks: TGTX, BIIB, INSM, and BNTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIIB Biogen	$217.15 +0.8%	$209.57	$135.39 ▼ $225.80	$31.83B	0.17	662,067 shs	1.08 million shs
BNTX BioNTech	$96.73 +0.3%	$96.98	$79.52 ▼ $124.00	$24.38B	1.29	1.68 million shs	1.18 million shs
INSM Insmed	$129.41 +1.7%	$117.76	$90.39 ▼ $212.75	$28.26B	0.82	1.74 million shs	1.70 million shs
TGTX TG Therapeutics	$53.89 -2.7%	$53.64	$26.76 ▼ $59.30	$8.48B	1.67	1.71 million shs	1.37 million shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIIB Biogen	+0.80%	-1.67%	+3.96%	+8.55%	+52.27%
BNTX BioNTech	+0.34%	-6.78%	+4.30%	+6.84%	-4.23%
INSM Insmed	+1.67%	+2.47%	-2.17%	+32.25%	-11.32%
TGTX TG Therapeutics	-2.71%	-3.75%	+8.87%	+8.82%	+69.31%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIIB Biogen	$217.15 +0.8%	$209.57	$135.39 ▼ $225.80	$31.83B	0.17	662,067 shs	1.08 million shs
BNTX BioNTech	$96.73 +0.3%	$96.98	$79.52 ▼ $124.00	$24.38B	1.29	1.68 million shs	1.18 million shs
INSM Insmed	$129.41 +1.7%	$117.76	$90.39 ▼ $212.75	$28.26B	0.82	1.74 million shs	1.70 million shs
TGTX TG Therapeutics	$53.89 -2.7%	$53.64	$26.76 ▼ $59.30	$8.48B	1.67	1.71 million shs	1.37 million shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIIB Biogen	+0.80%	-1.67%	+3.96%	+8.55%	+52.27%
BNTX BioNTech	+0.34%	-6.78%	+4.30%	+6.84%	-4.23%
INSM Insmed	+1.67%	+2.47%	-2.17%	+32.25%	-11.32%
TGTX TG Therapeutics	-2.71%	-3.75%	+8.87%	+8.82%	+69.31%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BIIB Biogen	2.58	Moderate Buy	$230.14	5.98% Upside
BNTX BioNTech	2.68	Moderate Buy	$126.00	30.26% Upside
INSM Insmed	3.00	Buy	$205.52	58.81% Upside
TGTX TG Therapeutics	2.33	Hold	$63.00	16.90% Upside

Current Analyst Ratings Breakdown

Latest TGTX, BIIB, INSM, and BNTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/10/2026	BIIB Biogen	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$242.00
9/10/2026	BIIB Biogen	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Reduce	$165.00 ➝ $175.00
9/8/2026	BNTX BioNTech	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$128.00 ➝ $105.00
9/7/2026	TGTX TG Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
9/3/2026	BIIB Biogen	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$225.00 ➝ $245.00
9/1/2026	TGTX TG Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$78.00
8/31/2026	BNTX BioNTech	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$142.00 ➝ $136.00
8/25/2026	BIIB Biogen	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$240.00 ➝ $260.00
8/13/2026	BIIB Biogen	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$300.00
8/12/2026	BIIB Biogen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
8/10/2026	INSM Insmed	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$185.00 ➝ $195.00

(Data available from 9/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BIIB Biogen	$9.89B	3.24	$22.81 per share	9.52	$124.45 per share	1.74
BNTX BioNTech	$2.65B	9.23	$1.34 per share	72.20	$96.59 per share	1.00
INSM Insmed	$1.14B	24.84	N/A	N/A	$3.46 per share	37.40
TGTX TG Therapeutics	$616.29M	13.38	$2.73 per share	19.77	$4.08 per share	13.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BIIB Biogen	$1.29B	$5.65	38.43	13.48	2.38	8.32%	11.18%	6.88%	10/29/2026 (Estimated)
BNTX BioNTech	-$1.29B	-$7.83	N/A	N/A	N/A	-63.54%	-6.86%	-6.00%	11/3/2026 (Estimated)
INSM Insmed	-$1.28B	-$4.11	N/A	49.58	N/A	-76.94%	-123.94%	-44.30%	10/29/2026 (Estimated)
TGTX TG Therapeutics	$447.18M	$2.74	19.67	20.34	2.37	55.22%	73.49%	34.14%	11/2/2026 (Estimated)

Latest TGTX, BIIB, INSM, and BNTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	INSM Insmed	-$0.6724	-$0.06	+$0.6124	-$0.06	$395.50 million	$425.49 million
8/4/2026	Q2 2026	BNTX BioNTech	-$2.3983	-$2.5340	-$0.1357	-$3.70	$180.18 million	$122.31 million
8/3/2026	Q2 2026	TGTX TG Therapeutics	$0.3057	$0.05	-$0.2557	$0.05	$229.77 million	$240.34 million
7/29/2026	Q2 2026	BIIB Biogen	$2.94	$3.60	+$0.66	$0.66	$2.46 billion	$2.74 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
BNTX BioNTech	$1.53	1.58%	N/A	N/A	N/A
INSM Insmed	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BIIB Biogen	0.39	1.87	1.26
BNTX BioNTech	0.01	7.85	7.80
INSM Insmed	0.74	3.72	3.40
TGTX TG Therapeutics	1.23	4.27	3.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BIIB Biogen	87.93%
BNTX BioNTech	15.52%
INSM Insmed	N/A
TGTX TG Therapeutics	58.58%

Insider Ownership

Company	Insider Ownership
BIIB Biogen	0.25%
BNTX BioNTech	19.20%
INSM Insmed	2.10%
TGTX TG Therapeutics	8.87%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BIIB Biogen	7,500	147.75 million	147.39 million	Optionable
BNTX BioNTech	7,807	252.88 million	204.33 million	Optionable
INSM Insmed	1,664	218.38 million	213.80 million	Optionable
TGTX TG Therapeutics	399	153.07 million	139.49 million	Optionable

TGTX, BIIB, INSM, and BNTX Headlines

Recent News About These Companies

VIRGINIA RETIREMENT SYSTEMS ET Al Invests $2.17 Million in TG Therapeutics, Inc. $TGTX

September 11 at 4:55 AM | marketbeat.com

TG Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference

September 10 at 7:51 AM | quiverquant.comQ

TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 10 at 7:30 AM | globenewswire.com

TG Therapeutics (NASDAQ:TGTX) Rating Lowered to "Strong Sell" at Zacks Research

September 9 at 7:05 AM | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Given Average Recommendation of "Hold" by Analysts

September 7, 2026 | americanbankingnews.com

Wellington Management Group LLP Increases Stock Position in TG Therapeutics, Inc. $TGTX

September 6, 2026 | marketbeat.com

AXQ Capital LP Takes Position in TG Therapeutics, Inc. $TGTX

September 6, 2026 | marketbeat.com

TG Therapeutics to Participate in the Cantor Global Healthcare Conference

September 3, 2026 | globenewswire.com

Corient Private Wealth LP Purchases Shares of 39,081 TG Therapeutics, Inc. $TGTX

September 3, 2026 | marketbeat.com

HC Wainwright Reiterates "Buy" Rating for TG Therapeutics (NASDAQ:TGTX)

September 3, 2026 | americanbankingnews.com

IBD stock of the day, TG Therapeutics, eyes breakout after topping early buy point

September 2, 2026 | msn.com

TG Therapeutics (TGTX) Up 15.1% Since Last Earnings Report: Can It Continue?

September 2, 2026 | zacks.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Rating of "Hold" from Analysts

September 2, 2026 | marketbeat.com

TGTX Stock Bounces Back as Analyst Downplays Threat from Novartis

September 1, 2026 | profitconfidential.comP

TGTX stock pares opening losses after analyst dismisses competition from Novartis

September 1, 2026 | msn.com

TG Therapeutics' (TGTX) Buy Rating Reaffirmed at HC Wainwright

September 1, 2026 | marketbeat.com

Jupiter Topco LLC Buys New Holdings in TG Therapeutics, Inc. $TGTX

September 1, 2026 | marketbeat.com

The Manufacturers Life Insurance Company Invests $4.27 Million in TG Therapeutics, Inc. $TGTX

September 1, 2026 | marketbeat.com

Legal & General Group Plc Invests $17.70 Million in TG Therapeutics, Inc. $TGTX

August 31, 2026 | marketbeat.com

Man Group plc Makes New Investment in TG Therapeutics, Inc. $TGTX

August 30, 2026 | marketbeat.com

Algert Global LLC Lowers Stock Position in TG Therapeutics, Inc. $TGTX

August 29, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TGTX, BIIB, INSM, and BNTX Company Descriptions

Biogen NASDAQ:BIIB

$217.15 +1.72 (+0.80%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$216.80 -0.35 (-0.16%)

As of 09/11/2026 07:30 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

BioNTech NASDAQ:BNTX

$96.73 +0.33 (+0.34%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$97.10 +0.37 (+0.38%)

As of 09/11/2026 07:59 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Insmed NASDAQ:INSM

$129.41 +2.13 (+1.67%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$129.22 -0.19 (-0.14%)

As of 09/11/2026 07:56 PM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

TG Therapeutics NASDAQ:TGTX

$53.89 -1.50 (-2.71%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$53.86 -0.02 (-0.05%)

As of 09/11/2026 07:30 PM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TGTX, BIIB, INSM, and BNTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TGTX, BIIB, INSM, and BNTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TGTX, BIIB, INSM, and BNTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TGTX, BIIB, INSM, and BNTX Company Descriptions

Biogen NASDAQ:BIIB

BioNTech NASDAQ:BNTX

Insmed NASDAQ:INSM

TG Therapeutics NASDAQ:TGTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TGTX, BIIB, INSM, and BNTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TGTX, BIIB, INSM, and BNTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TGTX, BIIB, INSM, and BNTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TGTX, BIIB, INSM, and BNTX Company Descriptions

Biogen NASDAQ:BIIB

BioNTech NASDAQ:BNTX

Insmed NASDAQ:INSM

TG Therapeutics NASDAQ:TGTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools